Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Receives $57.80 Average Price Target from Brokerages

Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Get Free Report) have earned a consensus rating of "Buy" from the nine analysts that are presently covering the stock, Marketbeat reports. Eight research analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price objective among brokers that have covered the stock in the last year is $53.50.

A number of brokerages have issued reports on ARCT. HC Wainwright restated a "buy" rating and set a $60.00 target price on shares of Arcturus Therapeutics in a research report on Thursday, April 10th. Scotiabank began coverage on shares of Arcturus Therapeutics in a research report on Wednesday. They set a "sector outperform" rating and a $32.00 price target on the stock. Wall Street Zen upgraded shares of Arcturus Therapeutics from a "sell" rating to a "hold" rating in a research report on Thursday, May 22nd. Canaccord Genuity Group reduced their price target on shares of Arcturus Therapeutics from $68.00 to $66.00 and set a "buy" rating on the stock in a research report on Tuesday, May 13th. Finally, BTIG Research set a $48.00 price target on shares of Arcturus Therapeutics and gave the stock a "buy" rating in a research report on Monday, March 10th.

Hedge Funds Weigh In On Arcturus Therapeutics

A number of institutional investors have recently made changes to their positions in the stock. Byrne Asset Management LLC boosted its stake in shares of Arcturus Therapeutics by 89.8% in the 1st quarter. Byrne Asset Management LLC now owns 2,885 shares of the biotechnology company's stock valued at $31,000 after purchasing an additional 1,365 shares in the last quarter. US Bancorp DE grew its holdings in shares of Arcturus Therapeutics by 218.9% during the 1st quarter. US Bancorp DE now owns 3,393 shares of the biotechnology company's stock valued at $36,000 after purchasing an additional 2,329 shares during the last quarter. Virtus ETF Advisers LLC grew its holdings in shares of Arcturus Therapeutics by 38.8% during the 4th quarter. Virtus ETF Advisers LLC now owns 4,051 shares of the biotechnology company's stock valued at $69,000 after purchasing an additional 1,132 shares during the last quarter. KLP Kapitalforvaltning AS bought a new position in shares of Arcturus Therapeutics during the 4th quarter valued at $71,000. Finally, GAMMA Investing LLC grew its holdings in shares of Arcturus Therapeutics by 3,482.9% during the 1st quarter. GAMMA Investing LLC now owns 5,231 shares of the biotechnology company's stock valued at $550,000 after purchasing an additional 5,085 shares during the last quarter. Institutional investors own 94.54% of the company's stock.

Arcturus Therapeutics Trading Up 7.7%

Shares of Arcturus Therapeutics stock traded up $0.91 during trading hours on Friday, reaching $12.73. 432,258 shares of the company's stock were exchanged, compared to its average volume of 446,958. The company has a 50 day moving average of $11.30 and a two-hundred day moving average of $14.82. Arcturus Therapeutics has a fifty-two week low of $8.04 and a fifty-two week high of $45.00. The stock has a market cap of $345.25 million, a P/E ratio of -5.73 and a beta of 2.36.

Arcturus Therapeutics (NASDAQ:ARCT - Get Free Report) last issued its earnings results on Monday, May 12th. The biotechnology company reported ($0.52) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.58) by $1.06. The company had revenue of $29.38 million for the quarter, compared to analysts' expectations of $25.64 million. Arcturus Therapeutics had a negative net margin of 36.39% and a negative return on equity of 22.39%. As a group, analysts expect that Arcturus Therapeutics will post -2.22 earnings per share for the current fiscal year.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.